A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

GLP-1 receptor agonists (RAs) are associated with fewer headaches and visual symptoms, reduced medication use, and less need for procedures — including bariatric surgery — compared with conventional ...

The percentage of patients with a GLP-1 RA prescription before metabolic and bariatric surgery increased from 5.6% to 26.9% from 2020 to 2024.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on ...

Preliminary study shows GLP-1 receptor agonists alter alcohol response, suggesting potential for reducing cravings and ...

Longer treatment duration, not having diabetes, and using semaglutide were among the factors associated with better weight reduction over 12 months among patients taking GLP-1 receptor agonists (RA), ...

Novo Nordisk NVO continues to derive the bulk of its revenue from its blockbuster semaglutide (GLP-1 RA) therapies, Wegovy ...

The global GLP-1 market has been in the spotlight for the past couple of years as big pharma players realize its multi-billion-dollar potential and the untapped nature. It is currently dominated by ...

People taking GLP-1 receptor agonists appeared to be at elevated risk of rejection episodes after lung transplantation, a small, single-center cohort study suggested. In a retrospective review of 301 ...

The popularity of GLP-1-based drugs is testament to the importance of a drug that increases fat burning and lowers blood sugar. Now, a drug—taken in the form of a tablet—offers the outcome of ...